Ex-Ante-Transparenzbekanntmachung § 130a Abs. 8 SGB V Arzneimittelbezeichnung: KOVALTRY(R) Wirkstoff: Octocog alfa, ATC-Code B02BD28; JIVI(R) Wirkstoff: Damoctocog alfa pegol, ATC-Code B02BD31
TED · 514096-2026Voluntary ex-ante transparency noticeawardedNo deadline given
Who already wins at this buyer
Firms with recorded awards from AOK Bayern - Die Gesundheitskasse in this tender’s CPV categories — the incumbents you are bidding against.
| Firm | Wins | Awarded | Last win |
|---|---|---|---|
| AstraZeneca GmbH | 1 | — | 2026-07-24 |
| Bayer Vital GmbH | 1 | — | 2026-07-24 |
| Biotest GmbH & Co. KGaA | 1 | — | 2026-07-24 |
| Daiichi Sankyo Deutschland GmbH | 1 | — | 2026-06-22 |
| Incyte Biosciences Distribution B.V. | 1 | — | 2026-06-22 |
Full buyer profile: what AOK Bayern - Die Gesundheitskasse buys and who wins it →
CPV codes
33600000 Medical equipment & pharmaceuticalsDescription
Arzneimittelrabattvertrag § 130a Abs. 8 SGB V Arzneimittelbezeichnung: KOVALTRY(R) Wirkstoff: Octocog alfa ATC-Code B02BD28; JIVI(R) Wirkstoff: Damoctocog alfa pegol ATC-Code: B02BD31